{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"groups":[{"description":"Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults","id":"OG000","title":"RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants"}],"paramType":"NUMBER","populationDescription":"All 22 patients who received the selectively depleted transplant","reportingStatus":"POSTED","timeFrame":"100 days from transplant","title":"Acute GVHD (Grade 3 or 4) Using the CIBMTR Grading System.","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}